Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 3Depression 3Breast Neoplasms 2Anxiety Disorders 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Follicular 1Lung Neoplasms 1Hospice 1Hematopoietic and Lymphoid System Neoplasm 1Hematopoietic and Lymphatic System Neoplasm 1Hematologic Neoplasms 1Gynecologic Cancer 1Gastrointestinal Neoplasms 1Emotional Regulation 1Colonic Neoplasms 1Advanced Cancer 1Acute Pain 1

Interventions

pembrolizumab 155Gemcitabine 139Capecitabine 121Paclitaxel 118Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 92Cisplatin 89Irinotecan 87Carboplatin 84Radiosurgery 83Cyclophosphamide 70Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × Psychotherapy × Clear all
NCT07336238 2026-05-26

Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies

University of Washington

Phase 2 Recruiting
18 enrolled

Anxiety Disorders, Depression, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡